FDA Lifecycle Approach to Process Validation
Keywords:
FDA lifecycle, Validation guidance, Organizational functions, Training Risk analysis, DocumentationAbstract
FDA lifecycle approach approach described in the guidance integrates various strategies, approaches, and expectations that had been mentioned in several previously published documents, guidelines, and presentations. The concepts identified in the respective stages of the FDA process validation guidance—understanding, performance, and main¬tenance—serve as a model for all areas of validation. Implementation of the lifecycle approach in site validation programs has significant ramifications for the organization. Organizational functions previously “distant” from commercial processes are now integral to ongoing performance. Post-validation monitoring of process performance including timely responsiveness to data trends is an expectation. The lifecycle approach affects many areas of validation programs including organizational aspects, validation performance guidance specifics, risk analysis, training, and documentation. Senior and functional management support is needed to transition organizations to the lifecycle approach to validation. Risk analysis is key to development and prioritization of a suitable validation program that will be embraced and supported.
References
- McNally, Grace E., “Lifecycle Approach Process Valida¬tion, GMP by the Sea, Cambridge, MD. August 26, 2008.
- McNally, Grace E., “Lifecycle Approach Process Valida¬tion,” GMP by the Sea, Cambridge, MD. August 29, 2007.
- Famulare, Joseph, “Benefits of a Pharmaceutical Qual¬ity System,” PDA/FDA Joint Conference, Bethesda, MD, November 2, 2007.
- FDA, Draft Guidance for Industry, Process Validation: Gen¬eral Principles and Practices, November 2008.
- FDA, Quality Systems Approach to Pharmaceutical CGMP Regulations, September 2006.
- FDA, Pharmaceutical cGMPs for the 21st Century—A Risk- Based Approach, Final Report-Fall 2004, September 2004.
- FDA, Compliance Policy Guide 7132c.08. Section 490.100. Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval.
- Nasr, Moheb, “FDA Perspective on the Implementation of Quality by Design (QbD),” 9th APIC/CEFIC, Prague, Czech Republic, October 10, 2006.
- Yu, Lawrence X., Robert Lionberger, Michael C. Olson, Gordon Johnston, Gary Buehler, and Helen Winkle, “Quality by Design for Generic Drugs,” PharmTech.com, October 2, 2009.
- Winkle, Helen H., “Implementing Quality by Design,” PDA/FDA Joint Regulatory Conference, September 24, 2007.
- Yu, Lawrence X., “Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control,” Pharmaceutical Research online, January 10, 2008.
- FDA, Guide to Inspections of Oral Solid Dosage Forms. Pre/ Post Approval Issues for Development and Validation, Janu¬ary 1994.
- FDA, Guide to Inspections of Topical Drug Products, July 1994.
- FDA, Guide to Inspections, Oral Solutions and Suspensions, August 1994.
- www.ICH.org
- ICH, M4. The Common Technical Document for the Regis¬tration of Pharmaceuticals for Human Use.
- ICH, Q7. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, November 2000.
- GHTF, Study Group 3. Quality Management Systems—Pro¬cess Validation Guidance. Edition 2, January 2004.
- FDA, Medical Device Quality Systems Manual, January 1997.
- FDA, Guide to Inspections of Medical Device Manufacturers, Process Validation, 21 CFR 820.75, December 9, 1997.
- ISPE GAMP Testing SIG., “Key Principles and Consid¬erations for Testing of GxP Systems,” Pharmaceutical Engineering, Vol. 25, No. 6, Nov.-Dec. 2005.
Downloads
Published
Issue
Section
License
Copyright (c) IJSRCH
This work is licensed under a Creative Commons Attribution 4.0 International License.